<!DOCTYPE html>
<html class="theme-sleek astro-STCLZLJ5" lang="en">
  <head>
    <!-- Global Metadata -->
    <meta charset="utf-8">
    <meta name="viewport" content="width=device-width,initial-scale=1">
    <meta name="theme-color" media="(prefers-color-scheme: light)" content="#ffffff">
<meta name="theme-color" media="(prefers-color-scheme: dark)" content="#18181b">
<!-- 
  This is an example. 
  Use https://realfavicongenerator.net to generate the icons and manifest. 
-->
<link href="/favicon.ico" rel="shortcut icon">

    <!-- Primary Meta Tags --><title>Controlled release tablet formulation containing natural Δ9-tetrahydrocannabinol.</title>
<meta name="title" content="Controlled release tablet formulation containing natural Δ9-tetrahydrocannabinol.">
<meta name="description" content="Medical Cannabis Awareness New Zealand">


<!-- Open Graph / Facebook -->
<meta property="og:title" content="Controlled release tablet formulation containing natural Δ9-tetrahydrocannabinol.">
<meta property="og:description" content="Medical Cannabis Awareness New Zealand">
<meta property="og:type" content="article">
<meta property="og:url" content="https://mcanz.org.nz/blog/controlled-release-tablet-formulation-containing-natural-%CE%B49-tetrahydrocannabinol">

<meta property="article:published_time" content="2016-01-12T00:00:00.000Z">





<!-- Twitter -->
<meta property="twitter:title" content="Controlled release tablet formulation containing natural Δ9-tetrahydrocannabinol.">
<meta property="twitter:description" content="Medical Cannabis Awareness New Zealand">


<meta property="twitter:card" content="summary_large_image">


<!-- {twitter.url && <meta property="twitter:url" content={twitter.url} />} -->

  <link rel="stylesheet" href="/assets/_slug_.2607fc28.css" />
<link rel="stylesheet" href="/assets/_slug_.f022e152.css" /></head>

  <body class="text-text-body bg-bg-body max-w-3xl mx-auto px-4 sm:px-8 astro-STCLZLJ5">
    <header class="astro-FAM4J5CX">
  <a class="skip-to-main astro-FAM4J5CX" href="#main"> Skip to content</a>
  <nav class="astro-FAM4J5CX">
    <section class="astro-FAM4J5CX">
      <ul class="astro-FAM4J5CX">
        <li class="astro-FAM4J5CX"><!-- DO NOT FORMAT. IT ADDS AN EXTRA SPACE ON RENDERED CONTENT. --><a href="/" class="astro-FAM4J5CX header-link unset animated gradient-colors astro-C675TBRQ">Home</a>
</li>
        <li class="astro-FAM4J5CX"><!-- DO NOT FORMAT. IT ADDS AN EXTRA SPACE ON RENDERED CONTENT. --><a href="/blog" class="astro-FAM4J5CX active header-link unset animated gradient-colors astro-C675TBRQ">Blog</a>
</li>
      </ul>
    </section>
  </nav>
</header>

    <main id="main" class="astro-STCLZLJ5">
      <section class="blog-post astro-STCLZLJ5">
        <h1 class="title astro-STCLZLJ5">Controlled release tablet formulation containing natural Δ9-tetrahydrocannabinol.</h1>
        <time class="publish-date astro-STCLZLJ5">Jan 12, 2016</time>
        <article><p>Authors: <a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Punyamurthula%20NS%5BAuthor%5D&#38;cauthor=true&#38;cauthor_uid=26585693">Punyamurthula NS</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Hingorani%20T%5BAuthor%5D&#38;cauthor=true&#38;cauthor_uid=26585693">Hingorani T</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Adelli%20G%5BAuthor%5D&#38;cauthor=true&#38;cauthor_uid=26585693">Adelli G</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Gul%20W%5BAuthor%5D&#38;cauthor=true&#38;cauthor_uid=26585693">Gul W</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=ElSohly%20MA%5BAuthor%5D&#38;cauthor=true&#38;cauthor_uid=26585693">ElSohly MA</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Repka%20MA%5BAuthor%5D&#38;cauthor=true&#38;cauthor_uid=26585693">Repka MA</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Majumdar%20S%5BAuthor%5D&#38;cauthor=true&#38;cauthor_uid=26585693">Majumdar S</a></p><h3>Abstract</h3><p>Cannabinoids are increasingly being used in the treatment of chemotherapy-induced nausea and vomiting (CINV) because of their action on thecannabinoid receptors, CB1 and CB2. The currently marketed capsule formulations (sesame oil based and crystalline powder) are required to be administered frequently to maintain therapeutic levels, which leads to non-compliance. In the present study, oral controlled release tablet formulations of Δ9-tetrahydrocannabinol (THC) were prepared using the lipids Precirol® and Compritol®. Release profiles using THC-lipid matrices and/or with the lipids in the external phase (blend) were evaluated. The effect of directly compressible diluents lactose mixture (Ludipress®), dicalcium phosphate anhydrous (Emcompress®) and microcrystalline cellulose (Avicel® 102) on tablet characteristics and in vitro drug release was also investigated. Further, in vitro THC release in the presence of a lipase inhibitor, Pluronic® F68, was also studied. A 24 h zero-order THC release profile was obtained with a combination of Precirol® and Compritol® in the compression blend. Addition of Pluronic® F68 did not alter THC release in vitro. These optimized tablets were chemically and physically stable for 3 months, the last time point tested, at 25 °C/60% RH. The overall results demonstrate the feasibility of preparing oral THC tablets for once a day administration which can improve CINV management.</p><p>Article available on <a href="http://www.ncbi.nlm.nih.gov/pubmed/26585693">PubMed</a>, full article available for <a href="http://www.tandfonline.com/doi/abs/10.3109/03639045.2015.1118490?journalCode=iddi20">purchase here.</a></p></article>
      </section>
    </main>
    <footer class="astro-5AYKG27L">
  <div class="astro-5AYKG27L">

  </div>
</footer>


  
</body>


</html>